Press coverage about Merrimack Pharmaceuticals (NASDAQ:MACK) has trended somewhat positive recently, Accern Sentiment reports. The research firm rates the sentiment of news coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Merrimack Pharmaceuticals earned a news impact score of 0.20 on Accern’s scale. Accern also assigned news articles about the biopharmaceutical company an impact score of 47.4836739094489 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
MACK stock opened at $8.17 on Friday. The company has a market cap of $107.01, a P/E ratio of -1.44 and a beta of 1.80. Merrimack Pharmaceuticals has a fifty-two week low of $7.36 and a fifty-two week high of $39.90.
Separately, Robert W. Baird restated a “hold” rating and set a $12.00 target price on shares of Merrimack Pharmaceuticals in a research note on Thursday, March 15th.
WARNING: This article was first reported by BBNS and is the property of of BBNS. If you are viewing this article on another domain, it was copied illegally and reposted in violation of U.S. and international trademark & copyright laws. The legal version of this article can be accessed at https://baseballnewssource.com/2018/04/06/somewhat-favorable-press-coverage-somewhat-unlikely-to-impact-merrimack-pharmaceuticals-mack-stock-price/2030132.html.
Merrimack Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on biomarker-defined cancers in the United States. The company's clinical programs include MM-121, which is in Phase II clinical trial for the treatment of patients with heregulin positive non-small cell lung cancer; and MM-141, a human tetravalent bispecific antibody that is in Phase II clinical trial for treating patients with metastatic pancreatic cancer with high serum levels of free insulin-like growth factor 1.
Receive News & Ratings for Merrimack Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merrimack Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.